PL2983712T3 - Kompozycja makrocyklicznych laktonów, lewamizolu, aminocukru i dodatkowego środka przeciwpasożytniczego - Google Patents

Kompozycja makrocyklicznych laktonów, lewamizolu, aminocukru i dodatkowego środka przeciwpasożytniczego

Info

Publication number
PL2983712T3
PL2983712T3 PL14723640T PL14723640T PL2983712T3 PL 2983712 T3 PL2983712 T3 PL 2983712T3 PL 14723640 T PL14723640 T PL 14723640T PL 14723640 T PL14723640 T PL 14723640T PL 2983712 T3 PL2983712 T3 PL 2983712T3
Authority
PL
Poland
Prior art keywords
levamisole
composition
amino sugar
macrocyclic lactones
antiparasitic agent
Prior art date
Application number
PL14723640T
Other languages
English (en)
Inventor
Guy Francis De Rose
Sachin Pundlik Kolhe
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50694063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2983712(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of PL2983712T3 publication Critical patent/PL2983712T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PL14723640T 2013-04-12 2014-04-10 Kompozycja makrocyklicznych laktonów, lewamizolu, aminocukru i dodatkowego środka przeciwpasożytniczego PL2983712T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361811138P 2013-04-12 2013-04-12
PCT/US2014/033599 WO2014169092A1 (en) 2013-04-12 2014-04-10 Composition of macrocyclic lactones, levamisole, an amino sugar and an additional antiparasitic agent
EP14723640.0A EP2983712B1 (en) 2013-04-12 2014-04-10 Composition of macrocyclic lactones, levamisole, an amino sugar and an additional antiparasitic agent

Publications (1)

Publication Number Publication Date
PL2983712T3 true PL2983712T3 (pl) 2021-05-31

Family

ID=50694063

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14723640T PL2983712T3 (pl) 2013-04-12 2014-04-10 Kompozycja makrocyklicznych laktonów, lewamizolu, aminocukru i dodatkowego środka przeciwpasożytniczego

Country Status (11)

Country Link
US (1) US10307405B2 (pl)
EP (1) EP2983712B1 (pl)
BR (1) BR112015025875B1 (pl)
CL (1) CL2015002976A1 (pl)
CR (1) CR20150508A (pl)
ES (1) ES2846820T3 (pl)
MX (1) MX364170B (pl)
NZ (1) NZ712345A (pl)
PE (1) PE20151726A1 (pl)
PL (1) PL2983712T3 (pl)
WO (1) WO2014169092A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR102017010598A2 (pt) * 2017-05-19 2018-12-04 Flavio Alves Da Rocha composições veterinárias de liberação retardada para controle de ovos e larvas de helmintos nas fezes dos ruminantes, uso das composições, uso de antelmínticos com essa finalidade
WO2019101971A1 (en) * 2017-11-23 2019-05-31 Ceva Sante Animale Composition for treating parasites infestations
US11896594B2 (en) * 2018-09-05 2024-02-13 Zoetis Services Llc Palatable antiparasitic formulations
EP3815677B1 (en) 2019-10-30 2023-08-30 KRKA, d.d., Novo mesto Stable veterinary composition comprising moxidectin and imidacloprid

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE434277B (sv) 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4199569A (en) 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4144352A (en) 1977-12-19 1979-03-13 Merck & Co., Inc. Milbemycin compounds as anthelmintic agents
EP0165900A3 (de) 1984-06-08 1986-05-28 Ciba-Geigy Ag Neue Lactone, Verfahren zu ihrer Herstellung und ihre Verwendung in der Schädlingsbekämpfung
US4916154A (en) 1986-09-12 1990-04-10 American Cyanamid Company 23-Imino derivatives of LL-F28249 compounds
DE60116615T2 (de) 2000-04-27 2006-09-07 Sankyo Lifetech Co.Ltd. 13-substituierte milbemycinderivate, ihre herstellung und ihre verwendung gegen insekten und andere schadorganismen
US7348417B2 (en) 2003-08-07 2008-03-25 Wyeth Method of purifying moxidectin through crystallization
US7671034B2 (en) 2003-12-19 2010-03-02 Merial Limited Stabilized formulation of ivermectin feed premix with an extended shelf life
WO2006006021A2 (en) 2004-06-28 2006-01-19 Glenmark Pharmaceuticals Limited Stabilized pharmaceutical compositions of preferably a statin
WO2006069580A1 (en) 2004-12-30 2006-07-06 Cheminova A/S Oil-in-water formulation of avermectins
US7840123B2 (en) * 2007-06-21 2010-11-23 S.C. Johnson & Son, Inc. Diffusion device
DK2222168T3 (en) 2007-11-26 2018-12-03 Merial Inc SOLUTION SYSTEMS FOR POUR-ON FORMULAS TO FIGHT PARASITES
CA2734459A1 (en) 2008-08-18 2010-02-25 Intervet International B.V. Anthelmintic compositions
UA108641C2 (uk) * 2010-04-02 2015-05-25 Паразитицидна композиція, яка містить чотири активних агенти, та спосіб її застосування
PL2568980T3 (pl) 2010-05-12 2016-05-31 Merial Inc Pasożytobójcze preparaty lewamizolu i laktonów makrocyklicznych do wstrzykiwania
ES2659159T3 (es) * 2011-12-02 2018-03-14 Merial, Inc. Formulaciones de moxidectina inyectable de acción prolongada y nuevas formas cristalinas de moxidectina

Also Published As

Publication number Publication date
MX364170B (es) 2019-04-15
US10307405B2 (en) 2019-06-04
CL2015002976A1 (es) 2016-05-06
ES2846820T3 (es) 2021-07-29
BR112015025875B1 (pt) 2021-06-29
CR20150508A (es) 2015-11-18
MX2015014310A (es) 2016-02-16
EP2983712A1 (en) 2016-02-17
NZ712345A (en) 2016-04-29
EP2983712B1 (en) 2020-11-25
PE20151726A1 (es) 2015-11-18
WO2014169092A1 (en) 2014-10-16
US20160051524A1 (en) 2016-02-25
BR112015025875A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
HK1215567A1 (zh) 五元併六元雜環化合物、其製備方法、藥物組合物和應用
IL243608A0 (en) Substances with antiviral activity, preparations containing them and their uses
SG11201510179PA (en) Amino-triazine derivatives and pharmaceutical composition containing said derivatives
IL242347B (en) Macrocyclic compounds, their preparation and pharmaceutical compositions containing them
IL269622A (en) Preparation of (s,s)-secoisolariciresinol diglucoside and (r,r)- secoisolariciresinol diglucoside
HK1222563A1 (zh) 藥物組合物、製備及其用途
HK1210806A1 (en) Method for manufacturing immunocyte-containing composition, and cancer-treating composition
CL2015003672A1 (es) Fabricación de composición explosiva y plataforma de entrega, y métodos explosivos
EP3012256A4 (en) HETEROCYCLIC BENZIMIDAZOLE-2-PIPERAZINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARATION AND USE THEREOF
HK1225993A1 (zh) 糖胺聚糖的化合物、其製備方法及用途
IL246406A0 (en) History of imidazopyrazinone, their preparation and pharmaceutical preparations containing them
IL241359A0 (en) Converted indole-5-ol derivatives, preparations containing them and their uses
IL243227A0 (en) History of diaminocyclopentane carboxamide, their preparation and pharmaceutical preparations containing them
SI3349726T1 (sl) Mikrosfere, ki vsebujejo antihelmintske makrociklične laktone
EP2967102A4 (en) COMPOSITIONS AND METHODS OF ACTIVATING BDNF
PL2983712T3 (pl) Kompozycja makrocyklicznych laktonów, lewamizolu, aminocukru i dodatkowego środka przeciwpasożytniczego
HK1222993A1 (zh) 用於控制餐後血糖的組合物和方法
IL243223A0 (en) History of imidazole, their preparation and pharmaceutical preparations containing them
IL239873A0 (en) The history of piperidinylcarbazole, their preparation and pharmaceutical preparations containing them
HK1217670A1 (zh) 調配物、其製造方法和用途
IL242464A0 (en) Macrocyclic derivatives of urea as tafia inhibitors, their preparation and use as pharmaceuticals
IL284405A (en) Pharmaceutical composition, preparation and uses thereof